Schwab Charles Investment Management Inc. grew its holdings in Reata Pharmaceuticals, Inc. (NASDAQ:RETA) by 44.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 27,200 shares of the company’s stock after acquiring an additional 8,400 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.12% of Reata Pharmaceuticals worth $861,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Emerald Advisers Inc. PA boosted its position in shares of Reata Pharmaceuticals by 9.8% in the second quarter. Emerald Advisers Inc. PA now owns 406,426 shares of the company’s stock valued at $12,859,000 after acquiring an additional 36,227 shares during the period. Emerald Mutual Fund Advisers Trust boosted its position in shares of Reata Pharmaceuticals by 7.0% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 293,927 shares of the company’s stock valued at $9,300,000 after acquiring an additional 19,235 shares during the period. FMR LLC boosted its position in shares of Reata Pharmaceuticals by 40.6% in the first quarter. FMR LLC now owns 237,606 shares of the company’s stock valued at $5,382,000 after acquiring an additional 68,600 shares during the period. Geode Capital Management LLC boosted its position in shares of Reata Pharmaceuticals by 19.5% in the first quarter. Geode Capital Management LLC now owns 63,778 shares of the company’s stock valued at $1,444,000 after acquiring an additional 10,397 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Reata Pharmaceuticals in the first quarter valued at about $559,000. 15.68% of the stock is owned by institutional investors.

RETA has been the subject of a number of recent research reports. Zacks Investment Research cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Piper Jaffray Companies boosted their target price on shares of Reata Pharmaceuticals from $53.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, July 24th. Citigroup Inc. reissued a “buy” rating and issued a $87.00 target price (up previously from $39.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. Stifel Nicolaus reissued a “buy” rating and issued a $50.00 target price (up previously from $38.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. Finally, Robert W. Baird reissued an “outperform” rating and issued a $47.00 target price (up previously from $43.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $54.71.

Shares of Reata Pharmaceuticals, Inc. (RETA) opened at 30.28 on Wednesday. The company’s market cap is $790.40 million. The company’s 50-day moving average is $31.40 and its 200 day moving average is $28.34. Reata Pharmaceuticals, Inc. has a 52-week low of $18.51 and a 52-week high of $41.60.

WARNING: This report was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://theolympiareport.com/2017/11/01/schwab-charles-investment-management-inc-acquires-8400-shares-of-reata-pharmaceuticals-inc-reta.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.